Opinion|Videos|April 23, 2024
Gaps Between Guidelines and Clinical Practice Patterns in ASCVD
Experts on the management of ASCVD discuss clinical practice patterns of high-risk patients and the common reasons for clinicians not intensifying cholesterol treatment.
Advertisement
Episodes in this series
Advertisement
Related to this article
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
2
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
3
Survodutide Shows Cardiovascular Safety in SYNCHRONIZE-CVOT
4
How Pharmacists Help Patients Spot Patterns in Glucose Readings
5